Product Images Atorvastatin Calcium

This is a description of a medication containing atorvastatin with a dosage of 10 mg per film-coated tablet. The usual dosage instructions can be found in the package insert. The product is manufactured by Northstar Rx LLC and Ammora Pharm Pvt. Ltd. in India. The tablets are stored at controlled room temperature and come in a container with 90 tablets. The NDC number for this product is 72603-282-01.*

This text provides information about Atorvastatin Calcium tablets, USP, containing 20 mg of atorvastatin per tablet. The usual dosage and storage instructions are included. The tablets are manufactured in India by Amora Pharma Pyt Ltd. for Northstar Rx LLC, based in Memphis, TN. The product is dispensed in tight containers and falls under manufacturing license number 24/MDITS[2016/F/6. It is a product of India.*

This text provides information about a medication containing 40 mg of atorvastatin. It is presented in film-coated tablets and each tablet also contains calcium trihydrate. The usual dosage information can be found in the package insert. The tablets are recommended to be stored at 20° to 25°C. The medication is manufactured for Northstar Rx LLC in Memphis, TN, and manufactured by Amnora Pharma Pvt Ltd in Telangana, India. Each bottle contains 90 tablets, and the product is from India.*

This description is for Atorvastatin Calcium tablets, USP containing 90 tablets each with 80 mg of atorvastatin. The tablets are film-coated and have a total strength of 86.579 mg atorvastatin calcium. The usual dosage information is provided in the package insert. The tablets should be stored at a temperature between 20°C to 25°C. The medication is dispensed in tight containers and manufactured in India by Amorz Pharma Pvt. Ltd. for Northstar Rx LLC in Memphis, TN. The manufacturer's license number is 24/MDITS/2016/FIG 2103482.*

This text provides information on cumulative incidence (%) for Atorvastatin and Placebo, along with the hazard ratio (HR) and p-value. The data suggests a significant difference between the two groups in terms of incidence rates over a period of 3.5 years.*

This text provides information about the cumulative hazard percentage at different time intervals for Placebo and Atorvastatin treatments. It also includes Hazard Ratio (HR) with confidence interval and p-value for the comparison between the two treatments. This data relates to the time taken to reach the primary endpoint over a four-year follow-up period.*

This text provides data on the percentage of subjects experiencing an event, the comparison between two doses of Atorvastatin (10 mg and 80 mg), hazard ratio (HR) with confidence interval and p-value for cardiovascular endpoint analysis over time. It shows a potential benefit of Atorvastatin 80 mg compared to 10 mg in reducing the risk of major cardiovascular events.*